Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291057 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
A Phase 2 study, sponsored by Sun Pharmaceutical Industries.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00291057 is a Phase 2 study that was terminated before completion, run by Sun Pharmaceutical Industries. The registered enrollment target is 30 participants.
The verdict
NCT00291057, a Phase 2 study, was terminated before completion, sponsored by Sun Pharmaceutical Industries.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
Interventions
- DRUG MALG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291057
The ClinicalTrials.gov registry entry for NCT00291057 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MALG is the first listed.
NCT00291057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00291057 about?
NCT00291057 is a clinical study titled "Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice". In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and...
What is the current status of trial NCT00291057?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00291057?
The interventions under investigation include: MALG (DRUG).
Who is sponsoring clinical trial NCT00291057?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.